
Spero Therapeutics (SPRO), headquartered in Cambridge’s Central Square neighborhood, announced this week that two government agencies would give the company up to $54.2 million to continue developing a new antibiotic for complicated urinary tract infections. The news came just days after Novartis revealed it would shut down its antibiotics unit and and license out its drug candidates — including one for a complicated urinary tract infection.
Paratek (PRTK), which has offices in Boston and Philadelphia, is working on new antibiotics that are similar to tetracycline. An antibody-drug conjugate against Pseudomonas from Visterra, a company in Waltham, Mass., that Otsuka bought for $430 million, is in the preclinical stage. Entasis Therapeutics, which also has its headquarters in Waltham, is working on antibiotics for several different infections, including gonorrhea.
What is it?
STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.